Christopher Enny

3.5k citations

21 papers · 962 indexed · h-index 14

Impact in

Biochemistry top 2%
- Blood transfusion and management
Hematology top 2%
- Erythropoietin and Anemia Treatment
- Multiple Myeloma Research and Treatments

Papers in ⓘ

Hematology 10
- Erythropoietin and Anemia Treatment 5
- Multiple Myeloma Research and Treatments 5
Genetics 6
- Chronic Lymphocytic Leukemia Research 3

Co-authors: Howard L. Corwin (4 shared papers)Theodore Colton (3 shared papers)K. Dean Gubler (3 shared papers)Robert M. Rodriguez (3 shared papers)Andrew Gettinger (3 shared papers)Michael J. Corwin (3 shared papers)Ronald G. Pearl (3 shared papers)Helgi van de Velde (11 shared papers)
Journals: Blood (5 papers)Critical Care Medicine (3 papers)Journal of Clinical Oncology (2 papers)Spine (1 paper)Current Medical Research and Opinion (1 paper)
Partner nations: United States United Kingdom Canada

In The Last Decade

Christopher Enny

21 papers receiving 942 citations

Peers

Countries citing papers authored by Christopher Enny

Since Specialization

Citations

This map shows the geographic impact of Christopher Enny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Enny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Enny more than expected).

Fields of papers citing papers by Christopher Enny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Enny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Enny. The network helps show where Christopher Enny may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Enny, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Enny Line = papers co-authored together Christopher Enny links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial Critical Care Medicine ·Howard L. Corwin, Andrew Gettinger, Robert M. Rodriguez, Ronald G. Pearl, K. Dean Gubler, Christopher Enny, Theodore Colton, Michael J. Corwin	1999	230
2	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study Blood ·Donna Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard T. Heffner, Robert Vescio, Kevin Liu, Christopher Enny, Dixie‐Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo	2011	123
3	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL Blood ·Fritz Offner, Olga Samoilova, Evgenii A. Osmanov, Hyeon‐Seok Eom, Max S. Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoğlu	2015	98
4	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial The Lancet Oncology ·Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani	2011	81
5	An Open-Label, Randomized, Parallel-Group Study of Perioperative Epoetin Alfa Versus Standard of Care for Blood Conservation in Major Elective Spinal Surgery Spine ·Christopher P. Stowell, Stanley Jones, Christopher Enny, Wayne Langholff, G Leitz	2009	65
6	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma Journal of Clinical Oncology ·Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vídriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Deborah Ricci, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau	2012	58
7	Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin The Journal of Trauma: Injury, Infection, and Critical Care ·Lena M. Napolitano, Timothy C. Fabian, Kathleen Kelly, Jeffrey A. Bailey, Ernest F. J. Block, Wayne Langholff, Christopher Enny, Howard L. Corwin	2008	56
8	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Blood ·Donna Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard T. Heffner, Vishal Kukreti, Robert Vescio, Lixia Pei, Christopher Enny, Dixie‐Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo	2014	56
9	Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa Current Medical Research and Opinion ·Patrick Lefèbvre, Francis Vekeman, Brenda Sarokhan, Christopher Enny, Robert Provenzano, Pierre‐Yves Crémieux	2006	55
10	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects QJM ·Simon W Dubrey, Donna Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean Paul Fermand, Robert Vescio, Joan Bladé, Leonard T. Heffner, Hani Hassoun, X. Liu, Christopher Enny, Priya Ramaswami, Yusri Elsayed, Helgi van de Velde, Susan Mortimer, Andrew Cakana, Raymond L. Comenzo, (unknown)	2011	37
11	Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial* Critical Care Medicine ·Howard L. Corwin, Andrew Gettinger, Robert M. Rodriguez, Ronald G. Pearl, K. Dean Gubler, Christopher Enny, Theodore Colton, Michael J. Corwin	2001	21
12	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up British Journal of Haematology ·Heinz Ludwig, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vídriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Shalini Chaturvedi, Ö. Ataman, Christopher Enny, Huaibao Feng, Helgi van de Velde, Luísa Viterbo	2015	21
13	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial Journal of Hematology & Oncology ·Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie‐Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri Elsayed, Bertrand Coiffier	2012	17
14	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus Leukemia & lymphoma ·Georg Heß, Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Dolores Caballero, Cristina João, Mathias Witzens‐Harig, Isabelle Bence‐Bruckler, Seok‐Goo Cho, Wenjiong Zhou, Jeffrey L. Goldberg, Cristina Trambitas, Christopher Enny, Jessica Vermeulen, Shana Traina, Chiun‐Fang Chiou, Joris Diels, Martin Dreyling	2017	15
15	A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma Blood ·Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Michael Crump, Ofer Shpilberg, Róbert Hermann, Sudha Parasuraman, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani	2010	11
16	Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. Blood ·Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau	2009	5
17	EFFICACY OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE CRITICALLY ILL PATIENT Critical Care Medicine ·Howard L. Corwin, Andrew Gettinger, Robert M. Rodriguez, Ronald G. Pearl, K. Dean Gubler, Christopher Enny, Theodore Colton, Michael J. Corwin	1998	4
18	Phase II study of bortezomib, thalidomide, and dexamethasone /- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD Heinz Ludwig, Luísa Viterbo, Richard Greil, Ivan Špıčka, Roman Hájek, Anna Dmoszyńska, BL Paiva, María‐Belén Vídriales, Graça Esteves, Anne Marie Stoppa, Deborah Ricci, Andrew Cakana, Christopher Enny, H. Feng, Helgi van de Velde, Harousseau Jl	2010	4
19	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial Leukemia ·Ciara L. Freeman, Prasath Pararajalingam, Ling Jin, Sriram Balasubramanian, Aixiang Jiang, Wendan Xu, Michael Grau, Myroslav Zapukhlyak, Merrill Boyle, Brendan P. Hodkinson, Michael Schäffer, Christopher Enny, Sanjay Deshpande, Steven Sun, Jessica Vermeulen, Ryan D. Morin, David W. Scott, Georg Lenz	2022	3
20	Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy Annals of Oncology ·M. Crump, Adriana Scheliga, Jiří Mayer, Fritz Offner, Adriana Teixeira, Kazimierz Kuliczkowski, A.M. Liberati, C. Y. Okada, DL Esseltine, Christopher Enny, E. Zhu, H. Van de Velde, Y. A. Elsayed, B Coiffier	2011	1

About Christopher Enny

Christopher Enny is a scholar working on Hematology, Genetics, Biochemistry, Pathology and Forensic Medicine and Oncology, having authored 21 papers that have together received 962 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Erythropoietin and Anemia Treatment (5 papers), Multiple Myeloma Research and Treatments (5 papers), Viral-associated cancers and disorders (4 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers), Blood transfusion and management (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Biochemistry (263 citations), Hematology (425 citations), Genetics (255 citations), Critical Care and Intensive Care Medicine (120 citations) and Nephrology (99 citations). Christopher Enny has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Howard L. Corwin, Theodore Colton, K. Dean Gubler, Robert M. Rodriguez, Andrew Gettinger, Michael J. Corwin, Ronald G. Pearl, Helgi van de Velde, Wayne Langholff and Andrew Cakana. Their work appears in journals such as Blood, Critical Care Medicine, Journal of Clinical Oncology, Spine and Current Medical Research and Opinion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact